JPMorgan Cuts Price Target on Zai Lab to $38 From $43, Maintains Overweight Rating
Zai Lab Analyst Ratings
Zai Lab Analyst Ratings
Zai Lab Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Zai Lab (ZLAB), Alphatec Holdings (ATEC)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)
Buy Rating Affirmed for Zai Lab Amid Strong Sales Performance and Positive Development Outlook
Zai Lab Analyst Ratings
Buy Rating on Zai Lab With a Target Price of $66 Amid Vyvgart's Growth Potential and Strategic Positioning
Buy Rating Affirmed for Zai Lab on Strong Product Performance and Upbeat Revenue Projections
Zai Lab's Growth and Pipeline Prompts Buy Rating: Analyst David Li's Financial Outlook and Price Objective
Analysts' Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), Globus Medical (GMED) and Zai Lab (ZLAB)
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Arcus Biosciences (RCUS) and Zai Lab (ZLAB)
Morgan Stanley Initiates Coverage On Zai Lab With Overweight Rating, Announces Price Target of $47.5
Zai Lab Analyst Ratings
Zai Lab Analyst Ratings
Zai Lab's Strong Sales Performance and Market Dominance Bolsters Buy Rating: An Analysis by David Li
Analysts Are Bullish on These Technology Stocks: Zai Lab (ZLAB), Navitas Semiconductor (NVTS)
Analysts Conflicted on These Technology Names: AUTO1 Group SE (OtherATOGF), Rivian Automotive (RIVN) and Zai Lab (ZLAB)
Analysts Offer Insights on Technology Companies: Klaviyo, Inc. Class A (KVYO), Zai Lab (ZLAB) and Mobileye Global, Inc. Class A (MBLY)